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Objectives/Hypothesis: To establish the relevance of the bone morphogenetic protein (BMP) signaling pathway in
human oral squamous cell carcinoma (OSCCA) cell lines and determine if there is a biologic impact of stimulating this path-
way with recombinant human (rh) BMP-2.
Study Design: In vitro laboratory investigations and in vivo analysis using an orthotopic animal model for oral cancer.
Methods: Gene expression profiles for BMP-2 and components of the BMP-signaling pathway were determined using
reverse transcriptase-polymerase chain reaction. In vivo effects were evaluated using Kaplan-Meier survival analysis and
studying histopathologic changes in established tumor xenografts with or without rhBMP-2 pretreatment. A phosphokinase
array was used to detect levels of activation in signaling kinases.
Results: The BMP-2 gene was expressed in 90% of the 30 OSCCA cell lines tested. Gene expression of all components of
the BMP-signaling pathway was highly conserved. Tumor xenografts established with rhBMP-2–treated cells showed more
rapid local growth that resulted in worse animal survival as compared to the control group. These tumors had a more poorly
differentiated morphology. Changes in protein kinases suggested interactions of BMP-2 signaling with the Wnt-b-catenin, and
Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathways.
Conclusions: Human OSCCA cell lines frequently express BMP-2 and all necessary components of the BMP-signaling
pathway. Exogenous treatment of human OSCCA cell lines with rhBMP-2 prior to engraftment in an orthotopic animal model
caused the subsequent tumors to be more locally aggressive with worse survival. Continued caution should be used for con-
sidering rhBMP-2 for reconstruction of bone defects in oral cancer patients.
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INTRODUCTION
Current methods for craniofacial bone reconstruc-
tion involve vascularized or non-vascularized autologous
bone grafts, which have inherent limitations and create
donor site morbidity. There are great prospects for
current reconstructive techniques to be replaced by
approaches using tissue engineering. Preclinical animal
models and clinical experience from orthopedics show
that bone morphogenetic proteins (BMPs) are critically
important osteoinductive molecules for these regenera-
tive approaches.1 Two recombinant human BMPs
(rhBMP-2 and rhBMP-7) are now commercially available
and have already led to improvements in the treatment
of patients undergoing surgery for spinal fusion and
long bone nonunions.2,3 Human recombinant BMP-2 is
also U.S. Food and Drug Administration-approved for
some orodental applications, but the use for patients
with craniomaxillofacial or mandibular defects after oral
cancer resection remains contraindicated due to the pau-
city of data regarding the biologic effects of BMPs on
human oral squamous cell carcinoma (OSCCA).4,5
The potential role of BMPs in malignant transfor-
mation and progression of cancer is poorly understood.6
Evidence of cancer development induced by rhBMP-2 at
the local application site has not been apparent in exten-
sive preclinical experience, and the incidence of
subsequent cancer development in orthopedic patients
treated with these proteins does not appear to be greater
than that of the general population.7,8 With regard to
oral carcinoma, a recent report showed that rhBMP-2
did not have any adverse effects on proliferation or
angiogenesis in human OSCCA cell lines when tested in
vitro or in vivo using an ectopic site animal model.9
However, Jin et al. studied 29 oral carcinomas by immu-
nohistochemistry and found that BMP-2/4, BMP-5, and
BMP type IA receptor (BMPR-IA) were expressed in
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73%, 73%, and 83% of tumors, respectively. They concluded
that the BMP pathway is involved in carcinogenesis of oral
epithelium.10 These authors, however, did not comprehen-
sively study the BMP signaling pathway components or
investigate whether BMPs produced adverse biologic effects
on any of the key processes of tumorigenesis as outlined by
Hanahan and Weinberg.11 Subsequently, Zhou et al. per-
formed gene microarray analysis with validation using
quantitative polymerase chain reaction (PCR) on 25 oral
tongue squamous cell carcinomas.12 These investigators
found that increased BMP-2 gene expression was associated
with regional lymph node metastasis and extracapsular
spread within the metastatic lymph node, an established
marker of particularly poor prognosis.
There are no unifying conclusions that can be made
from the currently available data as to whether rhBMP-2
promotes, inhibits, or has no role in tumorigenesis of oral
carcinoma. From a practical standpoint, our knowledge in
this area needs to be increased before considering the trans-
lation of basic science advances in bone tissue engineering
using BMPs for reconstruction of craniomaxillofacial and
mandible defects in patients treated for OSCCA.
The objectives of this study were 1) to determine
the gene expression profile for BMP-2 and the compo-
nents of the BMP-signaling pathway in a large number
of human OSCCA cell lines, 2) to detect whether stimu-
lation of the BMP-2 signaling pathway has adverse
biologic effects in vivo on xenografts established from
human OSCCA cell lines in an orthotopic animal model,
and 3) to establish if rhBMP-2 treatment changes
expression profiles of protein kinases involved with
tumorigenesis in an oral cancer cell line.
MATERIALS AND METHODS
Cell Culture and Media
Twenty-seven human oral squamous carcinoma cell lines
were provided by Dr. Susanne M. Gollin (University of Pitts-
burgh, Pittsburgh, PA; UPCI:SCC). Cells were maintained in
minimum essential medium (MEM) (Invitrogen, Carlsbad, CA)
supplemented with Earle’s salt, L-glutamine, 1X NEAA, 10% fe-
tal bovine serum (FBS), and gentamicin. Three human oral
squamous carcinoma cell lines were provided by Dr. Thomas E.
Carey (University of Michigan, Ann Arbor, MI; UMSCC). These
cells and MG-63, an osteosarcoma-derived osteoblastic cell line,
were grown in Dulbecco’s modified Eagle’s medium (Mediatech
Inc., Manasses, VA) supplemented with 4.5 g/L glucose, L-gluta-
mine, 10% FBS, 1X NEAA, and penicillin-streptomycin.
Cultures were maintained at 37C in an atmosphere of 5% CO2.
All 30 cell lines were derived from previously untreated primary
disease sites, including the tongue, alveolar ridge, retromolar
trigone, buccal, and floor-of-mouth subsites.
Gene Expression Profiling by Reverse
Transcriptase-Polymerase Chain Reaction
Total RNA was isolated by TRIzol Reagent (Invitrogen)
according to the manufacturer’s protocol. Reverse transcription
to produce first strand cDNA was performed with 2 lg of total
RNA by High-Capacity cDNA Reverse Transcription kit with
RNase inhibitor (Applied Biosystems, Foster City, CA) in
accordance with the manufacturer’s protocols. The BMP-2,
BMP receptors, and Smads transcripts were amplified from the
cDNA by conventional PCR using gene-specific primers13–18
(Table I). For BMP-2 gene expression, normal human oral
mucosa was used as negative control, and MG-63 was used as
positive control.10,19 Each sample was tested in duplicate in
three independent experimental runs.
Establishment of Xenografts
All procedures involving animals were performed in accord-
ance with protocols approved by the Animal Studies Committee
at the Washington University School of Medicine. Six-week-old
athymic NCr-nu/nu males were purchased from the National
Cancer Institute (Frederick, MD) and housed under pathogen-
free conditions. Two oral squamous carcinoma cell lines were
used to establish xenografts. The cell line UMSCC-14Awas origi-
nally derived from an OSCCA from the floor of the mouth, and
the cell line UMSCC-74A was derived from an OSCCA from the
tongue. Preliminary tumor growth experiments established the
appropriate cell inoculums of 2  106 cells for UMSCC-14A and
1.5  106 cells for UMSCC-74A cells (data not shown). There
were two treatment groups for each cell line. Group 1 consisted of
cells that were initially kept in OPTIMEM reduced-serum me-
dium (Invitrogen) for 48 hours prior to injection to establish
control groups. Group 2 consisted of cells that were pretreated
with rhBMP-2 (Sigma-Aldrich, St. Louis, MO) at 100 ng/mL for
48 hours in OPTIMEM reduced-serum medium prior the injec-
tion. For orthotopic injections, cells were suspended in 50 ll of
phosphate buffered saline (Mediatech Inc.). After the mice were
anesthetized, cells were injected into the tongue tip using an
orthotopic nude mouse model for oral cancer that has been previ-
ously described.20 Xenograft formation and animal survival were
monitored and recorded weekly and at the end of the experiment.
The following criteria were used to terminate the experiment:
animal weight loss >25% of preinjected weight, inability to access
food/water, tumor ulceration/bleeding, respiratory symptoms, or
moribund appearance. The tumors were surgically removed, sep-
arated from surrounding tissue under the microscope, and
divided in half with one portion placed in 2% paraformaldehyde
and the other fresh frozen in liquid nitrogen. Regional lymph
nodes, brain, lung, and liver tissue were harvested from each ani-
mal and preserved in 2% paraformaldehyde.
Histopathologic Analysis
Formalin-fixed primary tumors were paraffin embedded and
serially sectioned at 5 lm thickness. Staining was performed with
standard technique using hematoxylin and eosin. All cases were
reviewed by the study pathologist (J.S.L.), who was blinded to the
treatment groups or other details regarding the tumors. Parame-
ters evaluated with light microscopy included tumors graded as
well, moderately, or poorly differentiated based on the degree of
maturation, nuclear to cytoplasmic ratios, presence of intercellular
bridges, and amount of extracellular keratin formation. Tumor
grade also included evaluation for spindle cell (or sarcomatoid) fea-
tures, wherein tumor cells develop fusiform, cigar-shaped nuclei
and grew in fascicles rather than nests. Other parameters eval-
uated included host inflammatory response (as none, minimal,
mild, or brisk), pattern of invasion (as pushing or infiltrative bor-
ders, and infiltrative consisting of small nests or individual cells
growing away from the tumor mass at the invasive front), perineu-
ral invasion, and lymphovascular space invasion. Other features,
such as mucosal ulceration, tumor necrosis, tumor degeneration
and vacuolar change, and peritumoral edema were noted as they
were observed. All tissue removed as regional lymph nodes, which
frequently included major salivary gland tissue, was submitted for
histologic examination. Only representative lung, liver, and brain
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tissue was submitted for histologic examination after gross
prosection.
Protein Kinase Array
UMSCC-74A cells were treated with or without rhBMP-2
(100 ng/mL) for 48 hours in OPTIMEM medium. Total protein
lysates were used to analyze the phosphorylation profiles of ki-
nases using a Human Phospho-Kinase array kit (R&D Systems,
Minneapolis, MN). Bio-Rad Chemiluminescent Imaging System
and Quantity One software (Bio-Rad Laboratories, Hercules,
CA) was used to analyze pixel density in each spot of the array.
The average signal of the pair of duplicate spots was normalized
on average signal from negative control spots as a background
value. The relative changes in the treated cells were determined
by comparing the corresponding signals to the control array.
Two independent experiments were performed.
Statistical Analyses
Relations between treatments (BMP-2 and control) and
histopathological characteristics (histological grade, host inflam-
matory response, pattern of invasion, perineural invasion, and
lymphovascular space invasion) within each cell line were ana-
lyzed by applying the Fisher exact test to the corresponding
contingency tables. The nonparametric Kaplan-Meier method
with right censoring was used for survival analysis. Differences
between the survival curves were tested using the Wilcoxon
test. All analyses were done using SAS 9.1.3 (SAS Institute
Inc., Cary, NC). P values <.05 were considered significant.
RESULTS
Gene Expression of BMP-2 and Components of
the BMP-Signaling Pathway in OSCCA
Cell Lines
Semiquantitative reverse transcriptase-polymerase
chain reaction analysis was performed to determine the
in vitro baseline gene expression levels of BMP-2,
BMPR-IA, BMPR-IB, BMPR-II, ActR-I, ActR-IIA, ActR-
IIB), BMPR-activating Smads (Smad 1, Smad 5, Smad 8,
and the common partner Smad (Smad 4) in 30 OSCCA
cell lines. The results shown in Figure 1 indicate that
TABLE I.
Gene-Specific Primer Sequences Used for Reverse Transcriptase-Polymerase Chain Reaction.
Name Primer sequence Product size (bp) Reference
BMP-2 For: 50-CGAGGTCCTGAGCGAGTTCGAG-30 837 13
Rev: 50-TGGCAGTAAAAGGCGTGATACC-30
BMPR-IA For: 50-GGGTGGGCACCAAACGCTAC-30 474 14
Rev: 50-CCACTCTAATTCCACCCATGCC-30
BMPR-IB For: 50-ACTTGCTGTATTGCTGACCTGG-30 512 14
Rev: 50-GGCTTTCTGCAGAGATGCTTAC-30
BMPR-II For: 50-AACATTTACAGAGTGCCTTTGATG-30 468 14
Rev: 50-AGCTGATTCACAGTCCCTCAAG-30
ActR-I For: 50-TTGCATAGCAGATTTGGGCCTG-30 556 14
Rev: 50-CAGTCAGGCCAGCATTAGGTCC-30
ActR-IIA For: 50-CGGGAAAATGGGAGCTGCTGC-30 467 14
Rev: 50-CAATCCCCGCAATTAACATAAGTG-30
ActR-IIB For: 50-GACACGGGAGTGCATCTACTAC-30 442 14
Rev: 50-GATGTCCACATGACCGTAGGG-30
Smad 1 For: 50-GTATGCCGAATGCCTTAGTG-30 486 15
Rev: 50-CACAGAGGTCAAGTATTATC-30
Smad 5 For: 50-CGGTAGCCACTGACTTTGAGTTAC-30 701 16
Rev: 50-AGCTGAAATGGACTTCCTGGTC-30
Smad 8 For: 50-CCATCAGCTCCCTCTTCTCC-30 429 15
Rev: 50-CGCTGTGTCTTGGTACCAGC-30
Smad 4 For: 50-GTGGAATAGCTCCAGCTATC-30 206 17
Rev: 50-CGGCATGGTATGAAGTACTCC-30
GAPDH For: 50-ACCACAGTCCATGCCATCAC-30 451 18
Rev: 50-TCCACCACCCTGTTGCTGTA-30
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the gene expression levels of BMP-2, BMPRs, and the
BMP-related Smads were highly conserved among the
great majority of OSCCA cell lines. Notably, 27 cell lines
(90%) expressed BMP-2 at baseline and usually at a sim-
ilar level of expression. Normal mucosa did not show
baseline gene expression of BMP-2.
In Vivo Biologic Effects of rhBMP-2 Treatment
Two OSCCA cell lines (UMSCC-14A and UMSCC-
74A) were selected for these experiments because their
baseline gene expression was representative of the com-
mon pattern observed among the 30 tested cell lines. All
recipient mice formed established tumors at the ortho-
topic site in both the treatment and control groups.
Time of xenograft formation and animal survival were
recorded. For the cells treated with rhBMP-2, the time
of xenograft formation was rapid (<1 week as compared
to 2 weeks for controls, data not shown). Animals in the
rhBMP-2 treated groups had significantly worse survival
as compared to the controls for both UMSCC-14A (P ¼
.0012) and UMSCC-74A (P ¼ .0004) (Fig. 2).
Histopathological Characteristics of Xenografts
of BMP-2–Treated Oral Carcinoma Cell Lines
Groups where the cell lines were treated with
rhBMP-2 prior to establishment of the xenografts consis-
tently showed changes in morphology toward more
poorly differentiated or undifferentiated tumors (Fig. 3).
The tumors went from showing nests of epithelioid tu-
mor cells with abundant cytoplasm and varying degrees
of keratin formation to poorly differentiated carcinomas,
many with spindle cell (or sarcomatoid) features.
This finding was statistically significant for UMSCC-14A
and trended toward being significant for UMSCC-74A
(Table II). Host inflammatory response was more intense
for the rhBMP-2 treatment group in UMSCC-14A, but
this was not observed for UMSCC-74A. Lymphovascular
space invasion was more prevalent in the rhBMP-2
treatment group for UMSCC-74A, but this did not reach
statistical significance. There was no observed difference
in pattern of invasion or perineural invasion for either
cell line. Evaluation of the cervical lymph nodes and dis-
tant organs showed no evidence of metastatic carcinoma
in the control or treatment groups for either cell line.
Effect of rhBMP-2 Treatment on Expression
Profiles of Signaling Kinases
Stimulation of the BMP-2 signaling pathway
resulted in alteration of phosphorylation levels of several
protein kinases in UMSCC-74A (Fig. 4). STAT3 and Lckc
Fig. 1. Gene expression in cell lines
for bone morphogenetic protein
(BMP)-2, BMP receptors (BMPRs),
and Smads. Reverse transcriptase-
polymerase chain reaction of normal
mucosa, MG-63, and 30 human oral
squamous carcinoma cell lines
derived from the tongue, alveolar
ridge, retromolar trigone, buccal,
and floor-of-mouth subsites.
Fig. 2. Recombinant human bone morphogenetic protein-2
(rhBMP-2) in vivo treatment effects on survival. (A) Kaplan-Meier
survival curve for animals injected orthotopically with UMSCC-14A
cells pretreated with rhBMP-2 or control. Animals injected with
rhBMP-2–treated cells had worse survival secondary to rapid local
tumor growth (P ¼ .0012). (B) Data summarized for two represen-
tative human oral cancer cell lines showing statistically significant
worse survival in the animals orthotopically injected with rhBMP-
2–treated cells.
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were upregulated, whereas b-catenin and AMPKa1 were
downregulated. It was difficult to determine statistically
significant differences in phosphorylation of some other
important kinases, because many had already been
phosphorylated at high levels.
DISCUSSION
The potential role of BMPs in malignant transfor-
mation and progression of cancer is poorly understood.
Investigation in this area has proceeded to varying
degrees in vitro and in vivo with different findings based
on the tumor site, tumor type, and BMP studied.6 For
OSCCA, previously reported data showed that BMP-2
and the receptor BMPR-IA were frequently expressed in
human tumors as detected by immunohistochemistry.10
Our study shows that a large number of human OSCCA
cell lines consistently expressed the BMP-2 gene and the
components of the BMP-2 signaling pathway. Further-
more, the in vitro effects on expression profiles of protein
kinases and the in vivo effects on animal survival after
transient exposure of OSCCA cell lines to rhBMP-2 sug-
gest that this pathway is functional and capable of being
activated. Our data also confirmed the findings from
other studies that the BMP-2 expression levels of normal
oral mucosal cells are absent to weak.10,21
The nude mice engrafted orthotopically with OSCCA
cell lines treated with rhBMP-2 had a significantly worse
survival rate as compared to the control group. A previ-
ous study showed that rhBMP-2 did not appear to have
an adverse biologic effect in OSCCA cells using a nude
mouse model with an ectopic site of tumor engraftment.9
Physiologically, the ectopic model does not mimic the com-
plexity of the microenvironment surrounding cancer cells
in the oral cavity, which could significantly influence the
tumor’s growth and its response to treatment.22 Thus, an
orthotopic nude mouse model for oral cancer was chosen
because it reliably allows for tumor engraftment in the
oral cavity and recapitulates the natural course of the
disease.20 In this study, metastases were not found in the
harvested cervical lymph nodes or distant organs, likely
due to the early deaths of the animals from the local dis-
ease burden.
Several histopathological characteristics were com-
pared in the xenografts, including known histologic
prognosticators for oral cancer.23 For the cells treated
with rhBMP-2, the xenografts consistently had a
change in morphology toward a poorly or dedifferenti-
ated appearance. This was statistically significant for
UMSCC-14A and trended toward significance for
UMSCC-74A. The moderately differentiated tumors
became more poorly differentiated (UMSCC-14A), and
the poorly differentiated tumors changed in morphology
Fig. 3. Xenograft histology from orthotopically established tumors. Representative histologic sections of xenografts established from
UMSCC-74A treated with control (A and C) or recombinant human bone morphogenetic protein-2 (B and D). The xenografts showed
changes in morphology toward more poorly differentiated tumors with spindle cell features. Hematoxylin and eosin; original magnification,
200 (A and B) and 400 (C and D).
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toward a spindle cell carcinoma (UMSCC-74A). This
morphologic change to a more mesenchymal phenotype
is suggestive of epithelial-mesenchymal transition
(EMT) and will be a focus of future investigations. Bone
morphogenetic proteins are already known to have a
role in the normal physiologic induction of EMT during
developmental processes and wound healing, and in the
pathological induction of EMT leading to more invasive
tumors for gastric and colon cancers.24–28
A human phospho-kinase array was used to address
the potential mechanisms underlying the more aggressive
tumor behavior observed in response to rhBMP-2 treat-
ment. This technique enables 46 different phosphorylated
cytoplasmic kinases to be screened in one sample of whole
cell protein lysate, which is a powerful tool for gaining a
global view of changes in signal transduction events
within cells. In our study, a significant finding was close
to an 8-fold decrease in expression of b-catenin. This was
unexpected, because BMP-2 acts synergistically with
b-catenin to promote osteoblast differentiation.29
Although activation of the Wnt-b-catenin pathway is fre-
quently observed in several cancers, the role of this
signaling pathway in OSCCA cells is poorly understood.30
Overexpression of b-catenin–promoted tumor growth in
an OSSCA cell line using an ectopic nude mouse model,
and a reduced cytoplasmic/nuclear pattern of b-catenin
was associated with an invasive growth pattern and
shorter survival in patients with oral cancers.31,32 How-
ever, a decreased level of b-catenin expression was
associated with worse overall survival in patients with
OSCCA and nasopharyngeal carcinoma.33,34 The roles of
downstream target genes of BMP-2 signaling and subse-
quent interactions with other signaling pathways in
OSCCA are not currently understood and warrant further
investigation with regard to the Wnt-b-catenin pathway.
Another interesting finding was the 2-fold increased
expression of STAT3 in the rhBMP-2 treated cells. The
signal transducer and activator of transcription (STAT)
proteins are important for relaying signals from activa-
tion of the epidermal growth factor receptor (EGFR).
Inhibition of EGFR-STAT3 signaling is thought to be a
possible therapeutic target for head and neck squamous
cell carcinoma, because it is constitutively active in
these cancers and causes adverse cellular effects through
mediating invasion, proliferation, EMT, and prevention
of apoptosis.35,36 There is currently a paucity of data
describing the interactions of the BMP-2 signaling path-
way with Janus kinase (JAK)-STAT signaling, which are
limited to studies investigating osteoblast differentia-
tion. These studies showed that BMP-2 activates this
TABLE II.
Recombinant Human Bone Morphogenetic Protein-2 Treatment Effects on Xenograft Histology.
Histopathologic Characteristics
UMSCC-14A UMSCC-74A
Control (%) BMP-2 (%) Fisher’s exact test (p-value) Control(%) BMP-2 (%) Fisher’s exact test (p-value)
Histological Grade:
Moderate 100 50 0.0294 0 0 0.1222
Poor 0 50 40 7
Poor with Spindle Cells 0 0 60 86
Spindle Cell Carcinoma 0 0 0 7
Host Inflammation:
None 11 0 0.0216 20 43 0.3875
Minimum 78 25 80 57
Mild 11 25 0 0
Brisk 0 50 0 0
Pattern of invasion:
Infiltrative 44 25 0.6199 60 64 1.0000
Pushing 56 75 40 36
Perineural invasion:
Yes 0 0 – 10 8 1.0000
No 100 100 90 92
Lymphovascular space invasion:
Yes 33 38 1.0000 0 31 0.1045
No 67 62 100 69
The histopathologic characteristics between tumors established after treatment with recombinant human bone morphogenetic protein-2 and control
were compared. P values for the treatment effects are shown. P values <.05 were considered significant. BMP-2 ¼ bone morphogenetic protein-2.
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signaling pathway through STAT3 phosphorylation in
human mesenchymal stem cells and accelerates early
osteoblastic differentiation through a STAT3-dependent
mechanism in mouse embryonic fibroblasts.37,38 These
data are consistent with our finding of increased in vitro
expression of phosphorylated STAT3 in response to
rhBMP-2 treatment and also might explain the
increased local tumor aggressiveness observed in vivo.
Further investigations focusing on the interactions
between the BMP2 and JAK/STAT signaling pathways
in oral cancer appear warranted.
For the baseline expression analysis of the cell
lines, only gene expression was determined rather than
also analyzing protein expression with Western blots or
doing fluorescence activated cell scanning analysis to
show that the BMP-receptors were located on the cell
surface. Independent of these additional investigations
being performed, we were able to show that the BMP-2
signaling pathway is functional in vitro based on the
observed changes in expression levels of kinases, and in
vivo based on the effects on the xenografts that were
established after rhBMP-2 treatment. Another limitation
of this study is the single dose that was used for rhBMP-
2 treatment, which was a standard dose used in other
published experimental studies (100 ng/mL) rather than
the dose used therapeutically in patients (1.5 mg/mL).
Although increasing the concentration of rhBMP-2 to
500 ng/mL did not show an additional dose-dependent
effect on proliferation or angiogenesis of OSCCA cell
lines, the biologic effect of supramaximal stimulation
similar to the dose used in patients could be unpredict-
able in this animal model and warrants future
investigation.9 Last, the cell inoculums that were calcu-
lated from the preliminary tumor growth experiments
were too high to compensate for the treatment effect,
which resulted in rapid death of the animals in these
groups. This did not allow for development of regional or
distant metastases for further analysis. These data now
provide important information that will assist us with
calculating cell inoculums used for future experiments.
CONCLUSION
The gene expression levels of BMP-2 and the compo-
nents of the BMP-signaling pathway are highly
conserved among most OSCCA cell lines. Using an ortho-
topic nude mouse model for oral cancer, treatment of
OSCCA cell lines with rhBMP-2 prior to engraftment
increases the local aggressiveness of tumor growth and
worsens animal survival. Histopathologic analysis of the
xenografts and observed changes in the expression profile
of protein kinases support further mechanistic studies
focusing on EMT, the JAK/STAT pathway, and the Wnt-
b-catenin pathway. Given the difference in expression lev-
els of BMP-2 in OSCCA cell lines as compared to normal
oral mucosa and the negative treatment effect, this sig-
naling pathway might be a novel therapeutic target for
treating OSCCA. Continued caution should be used for
considering the therapeutic use of rhBMP-2 for recon-
struction of bone defects in oral cancer patients.
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